Experienced in Polymorphous Low Grade Adenocarcinoma

Dr. Simran K. Sindhu

Hematology Oncology | Hematology | Oncology
3838 N Campbell Ave, 
Tucson, AZ 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Experienced in Polymorphous Low Grade Adenocarcinoma
3838 N Campbell Ave, 
Tucson, AZ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Simran Sindhu is a Hematologist Oncology specialist and a Hematologist in Tucson, Arizona. Dr. Sindhu is rated as an Experienced provider by MediFind in the treatment of Polymorphous Low Grade Adenocarcinoma. Her top areas of expertise are Angiosarcoma, Nasopharyngeal Carcinoma, Hemolytic Transfusion Reaction, and Inflammatory Breast Cancer. Dr. Sindhu is currently accepting new patients.

Her clinical research consists of co-authoring 4 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in AZ
Languages Spoken
English
Hindi
Punjabi
Spanish
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera
  • EPO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

3838 N Campbell Ave, Tucson, AZ 85719

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Enrollment Status: Recruiting
Publish Date: September 19, 2025
Intervention Type: Drug, Other, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 13, 2025
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
Evaluating the Role of Diffusion Tensor Imaging in Predicting Development of Chemotherapy Induced Peripheral Neuropathy in Patients With Breast Cancer
Evaluating the Role of Diffusion Tensor Imaging in Predicting Development of Chemotherapy Induced Peripheral Neuropathy in Patients With Breast Cancer
Enrollment Status: Completed
Publish Date: November 19, 2020
Intervention Type: Procedure, Other
Study Phase: Not Applicable
View 3 Less Clinical Trials

4 Total Publications

Neoadjuvant chemotherapy improves survival compared with concurrent chemoradiation alone in nasopharyngeal carcinoma patients with N3 disease.
Neoadjuvant chemotherapy improves survival compared with concurrent chemoradiation alone in nasopharyngeal carcinoma patients with N3 disease.
Journal: Head & neck
Published: February 15, 2019
Similar Doctors
Experienced in Polymorphous Low Grade Adenocarcinoma
Dr. Ricklie A. Julian
Hematology Oncology | Hematology | Oncology
Experienced in Polymorphous Low Grade Adenocarcinoma
Dr. Ricklie A. Julian
Hematology Oncology | Hematology | Oncology

Banner-University Medical Group

3838 N Campbell Ave, Bldg 1, 
Tucson, AZ 
 (0.1 miles away)
520-694-2873
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ricklie Julian is a Hematologist Oncology specialist and a Hematologist in Tucson, Arizona. Dr. Julian is rated as an Advanced provider by MediFind in the treatment of Polymorphous Low Grade Adenocarcinoma. Her top areas of expertise are Glioma, Pleuropulmonary Blastoma, Lung Cancer, and Head and Neck Squamous Cell Carcinoma (HNSCC). Dr. Julian is currently accepting new patients.

Experienced in Polymorphous Low Grade Adenocarcinoma
Dr. Donald J. Brooks
Hematology Oncology | Oncology | Hematology
Experienced in Polymorphous Low Grade Adenocarcinoma
Dr. Donald J. Brooks
Hematology Oncology | Oncology | Hematology

Arizona Oncology Associates PC

2070 W Rudasill Rd, 
Tucson, AZ 
 (4.8 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Donald Brooks is a Hematologist Oncology specialist and an Oncologist in Tucson, Arizona. Dr. Brooks is rated as a Distinguished provider by MediFind in the treatment of Polymorphous Low Grade Adenocarcinoma. His top areas of expertise are Paget Disease of the Breast, Breast Cancer, Non-Hodgkin Lymphoma, and Lung Cancer. Dr. Brooks is currently accepting new patients.

Experienced in Polymorphous Low Grade Adenocarcinoma
Dr. Sudhir R. Manda
Hematology Oncology | Hematology | Oncology
Experienced in Polymorphous Low Grade Adenocarcinoma
Dr. Sudhir R. Manda
Hematology Oncology | Hematology | Oncology

Tmc Medical Network

5301 E Grant Rd, 
Tucson, AZ 
 (4.0 miles away)
520-324-4230
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Sudhir Manda is a Hematologist Oncology specialist and a Hematologist in Tucson, Arizona. Dr. Manda is rated as a Distinguished provider by MediFind in the treatment of Polymorphous Low Grade Adenocarcinoma. His top areas of expertise are Multiple Myeloma, Colorectal Cancer, Familial Colorectal Cancer, and Lynch Syndrome. Dr. Manda is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sindhu's expertise for a condition
ConditionClose
      View All 18 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile